AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 111890 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric Oxygen (HBO)
Number of subjects: 82
Study 111890 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy in air
Number of subjects: 82
Study 30642657 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 13432
Study 30642657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13432
Study 28266234 — intervention group
Group type: EXPERIMENTAL
Intervention: Desogestrel
Number of subjects: 40
Study 28266234 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25845223 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus Lipitor (20 mg/tablet, one tablet per day for 6 weeks)
Number of subjects: 60
Study 25845223 — intervention group
Group type: COMPARATOR
Intervention: Lipitor (20 mg/tablet, one tablet per day for 6 weeks)
Number of subjects: 60
Study 22893038 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg isoxsuprine tablets four times per day (Group A, n=15)
Number of subjects: 40
Study 22893038 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone with hyaluronidase intralesional injections (Group B, n=15)
Number of subjects: 40
Study 22893038 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets (Group C, n=10)
Number of subjects: 40
Study 20537413 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer mentoring (PM)
Number of subjects: 60
Study 20537413 — intervention group
Group type: COMPARATOR
Intervention: Student mentoring (SM)
Number of subjects: 60
Study 19285788 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic sling procedure (IVS-02)
Number of subjects: 398
Study 19285788 — intervention group
Group type: COMPARATOR
Intervention: Transobturator sling procedure (IVS-04)
Number of subjects: 398
Study 19285788 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 398
Study 17484560 — intervention group
Group type: EXPERIMENTAL
Intervention: Frame-of-reference training
Number of subjects: 0
Study 17484560 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 17484560 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained consultants with competency modeling experience
Number of subjects: 0
Study 15340586 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized pain-management intervention
Number of subjects: 120
Study 15340586 — intervention group
Group type: COMPARATOR
Intervention: Distraction control group
Number of subjects: 120
Study 11641307 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine infusion in group A (n=27)
Number of subjects: 45
Study 11641307 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine infusion in group B (n=18)
Number of subjects: 45
Study 11641307 — intervention group
Group type: COMPARATOR
Intervention: L-arginine infusion in group C (n=11)
Number of subjects: 45
Study 11641307 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory blood pressure monitoring in group B (n=18)
Number of subjects: 45
Study 11641307 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (n=18)
Number of subjects: 45
Study 9855336 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous estradiol (various dosages)
Number of subjects: 8
Study 7977406 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-ended questionnaire
Number of subjects: 78
Study 7977406 — intervention group
Group type: COMPARATOR
Intervention: Partly prompted questionnaire
Number of subjects: 78
Study 7977406 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed prompting questionnaire
Number of subjects: 78
Study 2512462 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to physician-fee information (experimental group)
Number of subjects: 1375
Study 2512462 — intervention group
Group type: COMPARATOR
Intervention: Control group (no access to physician-fee information)
Number of subjects: 1375
Study 30857904 — intervention group
Group type: EXPERIMENTAL
Intervention: Abduction brace (ABG)
Number of subjects: 120
Study 30857904 — intervention group
Group type: COMPARATOR
Intervention: Open pouch arm sling (PASG)
Number of subjects: 120
Study 30857904 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ABG and PASG)
Number of subjects: 120
Study 28754491 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human C1 esterase inhibitor twice weekly (50 IU/kg; maximum 4200 IU)
Number of subjects: 35
Study 28754491 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human C1 esterase inhibitor once weekly (50 IU/kg; maximum 4200 IU)
Number of subjects: 35
Study 28754491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 26546883 — intervention group
Group type: EXPERIMENTAL
Intervention: HP diet (32% protein, 33% carbohydrate, 30% fat)
Number of subjects: 61
Study 26546883 — intervention group
Group type: COMPARATOR
Intervention: Higher-carbohydrate diet (HC, 22% protein, 51% carbohydrate, 22% fat)
Number of subjects: 61
Study 24304090 — intervention group
Group type: EXPERIMENTAL
Intervention: RFE under NMES
Number of subjects: 27
Study 24304090 — intervention group
Group type: EXPERIMENTAL
Intervention: RFE
Number of subjects: 27
Study 24304090 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional arm rehabilitation programme without NMES)
Number of subjects: 27
Study 22010226 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-lipid (0.82%) food particles
Number of subjects: 72
Study 22010226 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal-lipid (4.2%) food particles
Number of subjects: 72
Study 22010226 — intervention group
Group type: EXPERIMENTAL
Intervention: High-lipid (15.7%) food particles
Number of subjects: 72
Study 22010226 — intervention group
Group type: COMPARATOR
Intervention: Plastic grid floor (G)
Number of subjects: 72
Study 19233758 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (group A)
Number of subjects: 60
Study 19233758 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (group B)
Number of subjects: 60
Study 19233758 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (group C)
Number of subjects: 60
Study 17540212 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with reduced ejection fraction
Number of subjects: 0
Study 17540212 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with preserved ejection fraction
Number of subjects: 0
Study 17540212 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with reduced ejection fraction
Number of subjects: 0
Study 17540212 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with preserved ejection fraction
Number of subjects: 0
Study 15225187 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound examination at 12-14 gestational weeks including risk assessment for Down's syndrome
Number of subjects: 2026
Study 15225187 — intervention group
Group type: COMPARATOR
Intervention: Routine scan at 15-20 gestational weeks
Number of subjects: 2026
Study 12111923 — intervention group
Group type: EXPERIMENTAL
Intervention: Handsearching
Number of subjects: 714
Study 12111923 — intervention group
Group type: COMPARATOR
Intervention: MEDLINE searching
Number of subjects: 714
Study 12111923 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of handsearching and MEDLINE searching
Number of subjects: 714
Study 9585275 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine (0.1 mL/kg) with 1:200,000 epinephrine (0.5 microg/kg)
Number of subjects: 60
Study 9585275 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.01 mg/kg followed by test dose
Number of subjects: 60
Study 9585275 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study 9585275 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine followed by saline
Number of subjects: 60
Study 7644960 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy given by a physiotherapist
Number of subjects: 363
Study 7644960 — intervention group
Group type: COMPARATOR
Intervention: Placebo physiotherapy given by a physiotherapist
Number of subjects: 363
Study 7644960 — intervention group
Group type: COMPARATOR
Intervention: Usual care by a general practitioner (information and analgesics)
Number of subjects: 363
Study 2664882 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine as a comedication to haloperidol (24 mg haloperidol p.d.)
Number of subjects: 20
Study 2664882 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol alone (24 mg haloperidol p.d.)
Number of subjects: 20
Study 559593 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol 50 mg/kg body-weight
Number of subjects: 100
Study 559593 — intervention group
Group type: COMPARATOR
Intervention: Epicillin 1 g six hourly
Number of subjects: 100
Study 31838450 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 40
Study 31838450 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 40
Study 29688276 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (20 min, 2 mA; n = 14)
Number of subjects: 32
Study 29688276 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (n = 18)
Number of subjects: 32
Study 26686932 — intervention group
Group type: EXPERIMENTAL
Intervention: Permuted locus trial design for randomized controlled trial
Number of subjects: 0
Study 26686932 — intervention group
Group type: COMPARATOR
Intervention: Permuted locus trial
Number of subjects: 0
Study 25161696 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax ginseng (200 mg twice daily for four weeks)
Number of subjects: 10
Study 25161696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 22197630 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-sensorial stimuli to elicit CPD (CPD group, n=20)
Number of subjects: 39
Study 22197630 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=19)
Number of subjects: 39
Study 20495466 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose, extended-release mesalamine
Number of subjects: 0
Study 20495466 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (5-ASA)
Number of subjects: 0
Study 20495466 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Number of subjects: 0
Study 19094598 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 269
Study 19094598 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia
Number of subjects: 269
Study 16144533 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0
Study 16144533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11796769 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach treatment (mean of two sessions a week for 27.3 weeks)
Number of subjects: 110
Study 11796769 — intervention group
Group type: COMPARATOR
Intervention: Information provision (control group)
Number of subjects: 110
Study 11796769 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach treatment
Number of subjects: 110
Study 10518963 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivastal 50 mg LP (doses increased to 150-250 mg/day)
Number of subjects: 113
Study 7486602 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of nimodipine (0, 30, 60 mg)
Number of subjects: 25
Study 7486602 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple daily doses of nimodipine (up to 150 mg in 12 hours)
Number of subjects: 25
Study 2024732 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Interactive (CI)
Number of subjects: 126
Study 2024732 — intervention group
Group type: EXPERIMENTAL
Intervention: Videotape (V)
Number of subjects: 126
Study 6797752 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose propranolol (40 mg every 6 hours)
Number of subjects: 0
Study 6797752 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose propranolol (160 mg every 6 hours)
Number of subjects: 0
Study 31907022 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal advice
Number of subjects: 412
Study 31907022 — intervention group
Group type: EXPERIMENTAL
Intervention: Traffic light (TL) risk card
Number of subjects: 412
Study 31907022 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative light fluorescence (QLF) photograph
Number of subjects: 412
Study 31907022 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall WTP
Number of subjects: 412
Study 31476715 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 27271373 — intervention group
Group type: EXPERIMENTAL
Intervention: SST + IEMT
Number of subjects: 62
Study 27271373 — intervention group
Group type: EXPERIMENTAL
Intervention: SST + sham IEMT + NMES
Number of subjects: 62
Study 27271373 — intervention group
Group type: COMPARATOR
Intervention: SST
Number of subjects: 62
Study 25492721 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week physical exercise programme (PEP)
Number of subjects: 120
Study 25492721 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 25510692 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinn's Advantage Cleavage and Blastocyst media (QAC/QAB)
Number of subjects: 159
Study 25510692 — intervention group
Group type: COMPARATOR
Intervention: GIII series cleavage and blastocyst media (G1.3/G2.3)
Number of subjects: 159
Study 22805855 — intervention group
Group type: EXPERIMENTAL
Intervention: Opuntia ficus-indica (OFI)
Number of subjects: 6
Study 22805855 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 6
Study 19491817 — intervention group
Group type: EXPERIMENTAL
Intervention: Nootropil (piracetam) 100 mg/kg daily for 2 months
Number of subjects: 40
Study 19491817 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 19491817 — intervention group
Group type: EXPERIMENTAL
Intervention: Nootropil (piracetam)
Number of subjects: 40
Study 17211576 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal levels of Hsp32, Hsp70, and Hsp90 in patients with inflammation
Number of subjects: 0
Study 17211576 — intervention group
Group type: COMPARATOR
Intervention: Basal levels of Hsp32, Hsp70, and Hsp90 in controls
Number of subjects: 0
Study 17211576 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of Hsp levels
Number of subjects: 0
Study 17211576 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein and cytokines
Number of subjects: 0
Study 15346756 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Brånemark System implants
Number of subjects: 12
Study 15346756 — intervention group
Group type: COMPARATOR
Intervention: TiUnite Mk III implants
Number of subjects: 12
Study 11518440 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted garments worn on the paretic side for six weeks
Number of subjects: 24
Study 11518440 — intervention group
Group type: COMPARATOR
Intervention: Control group (no weighted garments)
Number of subjects: 24
Study 9715782 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10, 20, or 40 mg/day)
Number of subjects: 124
Study 9715782 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) (12.5, 25, or 50 mg/day)
Number of subjects: 124
Study 9715782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 9715782 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 124
Study 9715782 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 124
Study 8009196 — intervention group
Group type: EXPERIMENTAL
Intervention: Casodex 50 mg p.o. daily for seven to 12 months
Number of subjects: 5
Study 3066086 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol (40 mg/day)
Number of subjects: 8
Study 3066086 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg/day)
Number of subjects: 8
Study 3066086 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 8
Study 3066086 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol
Number of subjects: 8
Study 3066086 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 8
Study 30837426 — intervention group
Group type: EXPERIMENTAL
Intervention: AOM group (n=31)
Number of subjects: 107
Study 30837426 — intervention group
Group type: EXPERIMENTAL
Intervention: COME group (n=39)
Number of subjects: 107
Study 30837426 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=37)
Number of subjects: 107
Study 27364322 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral teriflunomide
Number of subjects: 324
Study 27364322 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous interferon beta‐1a
Number of subjects: 324
Study 26319218 — intervention group
Group type: EXPERIMENTAL
Intervention: Active assistive forced exercise
Number of subjects: 24
Study 26319218 — intervention group
Group type: COMPARATOR
Intervention: Passive assistive forced exercise
Number of subjects: 24
Study 23146571 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Number of subjects: 22
Study 23146571 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction
Number of subjects: 22
Study 16773696 — intervention group
Group type: EXPERIMENTAL
Intervention: Glivec (imatinib mesylate)
Number of subjects: 74
Study 16773696 — intervention group
Group type: COMPARATOR
Intervention: Not treated with Glivec (group A)
Number of subjects: 74
Study 14609783 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous phytonadione (0.5 mg for INR 6-10; 1 mg for INR >10)
Number of subjects: 61
Study 14609783 — intervention group
Group type: COMPARATOR
Intervention: Oral phytonadione (2.5 mg for INR 6-10; 5 mg for INR >10)
Number of subjects: 61
Study 14609783 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous phytonadione
Number of subjects: 61
Study 14609783 — intervention group
Group type: COMPARATOR
Intervention: Oral phytonadione
Number of subjects: 61
Study 10577849 — intervention group
Group type: EXPERIMENTAL
Intervention: ICE chemotherapy (ifosfamide, carboplatin, etoposide)
Number of subjects: 163
Study 8712561 — intervention group
Group type: EXPERIMENTAL
Intervention: ARROWgard catheter
Number of subjects: 191
Study 8712561 — intervention group
Group type: COMPARATOR
Intervention: Standard triple lumen catheter
Number of subjects: 191
Study 1861632 — intervention group
Group type: EXPERIMENTAL
Intervention: No calcium fluid (ionized calcium 0 mmol/L)
Number of subjects: 6
Study 1861632 — intervention group
Group type: COMPARATOR
Intervention: Control fluid (ionized calcium 1.25 mmol/L)
Number of subjects: 6
Study 1861632 — intervention group
Group type: EXPERIMENTAL
Intervention: No magnesium fluid (ionized magnesium 0 mmol/L)
Number of subjects: 6
Study 1861632 — intervention group
Group type: EXPERIMENTAL
Intervention: No albumin fluid (albumin 0 g/L)
Number of subjects: 6
Study 6226601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 1 g orally for 28 days
Number of subjects: 36
Study 6226601 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31286729 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with hyperbaric oxygen (HBO) therapy, treatment given once every day for 6 courses (5 days on, 2 days off).
Number of subjects: 26
Study 31286729 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy combined with HBO (control group).
Number of subjects: 26
Study 28317428 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization of non-infarct-related coronary arteries guided by fractional flow reserve (FFR), 295 patients
Number of subjects: 885
Study 28317428 — intervention group
Group type: COMPARATOR
Intervention: No revascularization of non-infarct-related coronary arteries, 590 patients
Number of subjects: 885
Study 26266376 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil (0.02 μg/kg/h)
Number of subjects: 132
Study 26266376 — intervention group
Group type: COMPARATOR
Intervention: Sufentanil plus dexmedetomidine (0.02 μg/kg/h each, Group D1)
Number of subjects: 132
Study 26266376 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (0.02 μg/kg/h) plus dexmedetomidine (0.04 μg/kg/h, Group D2)
Number of subjects: 132
Study 24340314 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard triple therapy (PPI-CA) with rabeprazole (20 mg), clarithromycin (500 mg), and amoxicillin (1 g) for 10 days.
Number of subjects: 104
Study 24340314 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (ST) with amoxicillin (1 g) on days 1 to 5, and metronidazole (500 mg) and clarithromycin (500 mg) on days 6 to 10.
Number of subjects: 104
Study 21630179 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby sleeping bag
Number of subjects: 15
Study 21630179 — intervention group
Group type: COMPARATOR
Intervention: Conventional bedding
Number of subjects: 15
Study 19803576 — intervention group
Group type: EXPERIMENTAL
Intervention: COMET + therapy as usual (TAU)
Number of subjects: 52
Study 19803576 — intervention group
Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 52
Study 16166239 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal exercise bout
Number of subjects: 15
Study 15273913 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheridan-Gardiner test (SGT)
Number of subjects: 30
Study 15273913 — intervention group
Group type: COMPARATOR
Intervention: Räder test (RT)
Number of subjects: 30
Study 15273913 — intervention group
Group type: EXPERIMENTAL
Intervention: Examination duration SGT
Number of subjects: 30
Study 15273913 — intervention group
Group type: COMPARATOR
Intervention: Examination duration RT
Number of subjects: 30
Study 11394984 — intervention group
Group type: EXPERIMENTAL
Intervention: Community risk-reduction campaign and distribution of female condoms and male condoms at Intervention sites.
Number of subjects: 12
Study 11394984 — intervention group
Group type: COMPARATOR
Intervention: Community risk-reduction campaign with male condoms only at Control sites.
Number of subjects: 12
Study 11394984 — intervention group
Group type: EXPERIMENTAL
Intervention: Female condom distribution at Intervention sites.
Number of subjects: 12
Study 9086380 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuro-PID controller with quadriceps stimulation
Number of subjects: 2
Study 9086380 — intervention group
Group type: COMPARATOR
Intervention: PID feedback controller
Number of subjects: 2
Study 7690165 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (high-dosage Trasylol scheme)
Number of subjects: 20
Study 7690165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2440683 — intervention group
Group type: EXPERIMENTAL
Intervention: aprindine 2 mg kg‐1
Number of subjects: 12